纳米晶体药物在不同给药系统中的研究进展  

Research progress of nanocrystalline drugs in different drug delivery systems

作　　者：郝耀廷 李彦辉 张慧聪 刘敬文 李春雷[1,2] HAO Yaoting;LI Yanhui;ZHANG Huicong;LIU Jingwen;LI Chunlei(School of Pharmacy,Hebei Medical University,Shijiazhuang 050031;CSPC Zhongqi Pharmaceutical Technology(Shijiazhuang)Co.,Ltd.,Shijiazhuang 050000,China)

机构地区：[1]河北医科大学药学院,石家庄050031 [2]石药集团中奇制药技术(石家庄)有限公司,石家庄050000

出　　处：《中国药科大学学报》2024年第4期548-556,共9页Journal of China Pharmaceutical University

摘　　要：纳米晶体技术通过减小粒子尺寸至纳米级别来改变难溶性药物的溶解度和溶出速率,该技术不受载体材料和包封率的限制,适用于多种给药途径,易于工业化生产,逐渐成为国际药学领域改善难溶性药物吸收、提高生物利用度的前沿性热点技术。本文介绍了纳米晶体药物(nanocrystal,NC)在肠外给药、眼部给药、经皮给药和肺部给药的吸收影响因素和面临的挑战,重点综述了这几种给药系统中已上市和处于临床前或临床试验阶段的NC,以期为难溶性药物纳米晶体制剂的进一步研发提供思路。Nanocrystal technology changes the solubility and dissolution rate of insoluble drugs by reducing the particle size to the nanometer level.This technology is not limited by carrier materials and encapsulation rate.It is suitable for a variety of drug delivery routes and easy for industrial production.It has gradually become a cuttingedge hot technology in the international pharmaceutical field to improve the absorption of insoluble drugs and improve their bioavailability.This article introduces the influencing factors and challenges of nanocrystal drugs(NC)in parenteral,ocular,transdermal and pulmonary administration,and focuses on nanocrystal drugs that have been marketed or are still in the preclinical or clinical trial stages of these delivery systems,in order to provide some insight for the further development of poorly soluble drug nanocrystal preparations.

关 键 词：纳米晶体 给药途径 稳定剂 药动学 生物利用度 

分 类 号：R944[医药卫生—药剂学]